The global fatty liver treatment market, valued at approximately USD 20 Billion in 2022, is anticipated to witness ...

Obesity is a chronic disease with many contributing factors ... and nutritionists to help guide and monitor obesity treatment ...

Results from Phase 2b FASCINATE-2 study of denifanstat published in The Lancet Gastroenterology & Hepatology Successful completion of end-of-Phase 2 interactions with FDA on the development of ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than ...

2 There are currently no treatments approved for MASLD, formerly known as nonalcoholic fatty liver disease. Instead, ...

Obesity is a chronic disease with many contributing factors; family history, access to healthy foods, hormonal and metabolic ...

Altimmune’s lead drug Pemvidutide demonstrates significant progress in obesity and liver health. See why ALT stock is a ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver ...

This treatment mediates long-term reversal of liver fibrosis ... Metabolic dysfunction-associated steatotic liver disease (MASLD), or "fatty liver disease," is the most common chronic liver disease ...

Research Progress on Multidisciplinary Intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Liver Cancer ...

Acute liver injury (ALI) caused by acetaminophen (APAP) overdose, hepatic ischemia-reperfusion injury (HIRI), and chronic ...

A recent study highlights the importance of zinc in patients with severe liver disease, especially those suffering from a brain-related complication called hepatic encephalopathy (HE). Conducted at ...